Lorem ipsum dolor

Lorem ipsum dolor sit amet ipsum dolor sit amet ipsum dolor sit amet



Lorem ipsum dolor sit amet

Stonehaven supports quantifiable growth of pharmaceutical firms by providing innovative Pharma strategies that create a competitive edge. We support Pharma initiatives from conception right through to final delivery at every stage of development.

Our unique approach involves working with you as a partner and sharing risks. Our approach sets us apart from other global management consultants in the Pharma space.

In Pharma, only one drug receives approval out of every 5,000 to 10,000 drugs that enter the pipeline.

You gain major advantages for being the first to bring a novel drug to market. However, the first-to-market advantage can diminish if your company fails to put the right strategies in place.

Our unique approach is to partner with you and work with you one-on-one in a collaborative effort to implement innovative strategies for every phase of drug development (pre-market to post-market), prevent expiration of patents, and ultimately put a stop to falling net income from a failing pipeline.

  • The Average time to develop a drug is 10-15 years
  • 70% of drugs today are potential first-in-class drugs
  • 1 out of 5,000-10,000 drugs receive approval

Business Insight for Pharma Firms

Experience matters. Our global consulting team of highly qualified and experienced individuals have the extensive knowledge across therapeutic areas, broad network and commitment to help Pharma companies succeed.

To be at the edge of the competition, growing Pharma firms can benefit from our insight on current industry trends, increasing competitive markets, desired industry outcomes, and optimal pricing structure in the midst of increasing pressure for Pharma firms to cut costs.

Growth Strategy for Small Pharma Firms

We target companies looking to grow. We help small Pharma companies grow by offering consultation support as early as necessary in the process and all the way through an expansion phase to a potential exit.

Many small Pharma firms do not have the resources to manage the successful development of a novel drug. We are committed to partnering with small firms to expand resources by customizing our compensation in the form of shared risks or working for equity.

Strategy Development for Large Pharma Firms

Pharma corporations with established pipelines need to fine-tune and transform their strategy development from the inside-out for better successful outcomes. We carefully evaluate your process and existing tools to ascertain whether they are matched to top the charts in Pharma’s growing competition.

Our team of experienced consultants guide Pharma firms towards selecting the right strategies for optimal outcomes. We focus on external factors that cause uncertainty such as pricing strategy, inconsistencies with regulations, and measuring drug outcomes.


Stefan Kundert Senior Advisor

Stefan received his MBA from the University of St. Gallen ...